Encouraging Results in Early Clinical Trials of Possible Treatment

Mar 06, 2017

Concert Pharmaceuticals, Inc. made a dramatic announcement over the weekend regarding the encouraging results of a possible alopecia areata treatment referred to as CTP-543, a modified version of the blood disorder treatment ruxolitinib commercially known as Jakafi®. To read more go to:  


Ryan Shazier Makes Time for a Fan
NAAF Celebrates New Era of Alopecia Areata Research at the Largest Dermatology Event of the Year